Latent reservoirs of HIV infection: flushing with IL-2?

Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2l. J Virol (2001) 1.34

Changes in thymic function in HIV-positive patients treated with highly active antiretroviral therapy and interleukin-2. Clin Exp Immunol (2001) 0.99

IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy? Oncoimmunology (2015) 0.75

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81

CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet (1999) 7.08

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49

Adverse effects of antiretroviral therapy. Lancet (2000) 4.84

Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet (1985) 4.83

Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38

The 2010 Royal Australasian College of Physicians' policy statement 'Circumcision of infant males' is not evidence based. Intern Med J (2012) 4.15

A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48

Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet (1985) 3.33

Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (1999) 3.28

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet (1998) 3.22

Primary HIV infection: host responses and intervention strategies. AIDS (1991) 2.80

Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med (1992) 2.65

Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet (1992) 2.60

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis (1996) 2.44

Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet (1998) 2.43

An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS (2000) 2.36

CD8+ lymphocyte responses to antiretroviral therapy of HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 2.23

Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017) AIDS (1994) 2.23

Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet (2013) 2.23

Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes. Science (1983) 2.21

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS (2001) 2.17

HIV disease progression in Australia in the time of combination antiretroviral therapies. Med J Aust (1998) 2.16

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med (2001) 2.14

Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS (1992) 2.08

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS (2001) 2.03

Incidence and risk factors for human immunodeficiency virus seroconversion in a cohort of Sydney homosexual men. Med J Aust (1989) 2.02

Use of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 to assess the performance of viral RNA quantitation tests. J Clin Microbiol (2000) 1.95

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis (2000) 1.91

Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis (1998) 1.88

CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS (1991) 1.85

The role of initial AIDS-defining illness in survival following AIDS. AIDS (1995) 1.82

Acquired immunodeficiency without evidence of HIV infection: national retrospective survey. BMJ (1994) 1.78

Vectors with restriction site banks. IV. pJRD184, a 3793-bp plasmid vector with 49 unique restriction sites. Gene (1985) 1.74

Ribavirin: a role in HIV infection? J Acquir Immune Defic Syndr (1990) 1.74

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis (1999) 1.70

The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis (1991) 1.69

Viral proteins expressed on the surface of murine leukemia cells. J Virol (1977) 1.60

Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise. Blood (1993) 1.54

Nosocomial outbreak of tuberculosis in an outpatient HIV treatment room. AIDS (1996) 1.46

Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44

The neurological features of early and 'latent' human immunodeficiency virus infection. Aust N Z J Med (1989) 1.42

Syringe HIV seroprevalence and behavioural and demographic characteristics of intravenous drug users in Sydney, Australia, 1987. AIDS (1988) 1.41

Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group. J Infect Dis (1998) 1.41

Bile acid malabsorption in HIV infected patients with chronic diarrhoea. Aust N Z J Med (1996) 1.40

HIV and hepatitis C coinfection within the CAESAR study. HIV Med (2004) 1.39

Survival of patients with the acquired immunodeficiency syndrome in Australia. Med J Aust (1989) 1.39

If it's the virus, why aren't we measuring it? Med J Aust (1995) 1.38

Chronic cryptosporidial diarrhoea and hyperimmune cow colostrum. Lancet (1987) 1.37

Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus. Virology (1989) 1.35

Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. Am J Epidemiol (1994) 1.34

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med (2003) 1.34

Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis (1997) 1.33

Appraisal of anti-smoking advertising by youth at risk for regular smoking: a comparative study in the United States, Australia, and Britain. Tob Control (2003) 1.32

Relation between dietary intake, serum concentrations, and retinal concentrations of lutein and zeaxanthin in adults in a Midwest population. Am J Clin Nutr (2001) 1.32

The end of the Injury Severity Score (ISS) and the Trauma and Injury Severity Score (TRISS): ICISS, an International Classification of Diseases, ninth revision-based prediction tool, outperforms both ISS and TRISS as predictors of trauma patient survival, hospital charges, and hospital length of stay. J Trauma (1998) 1.31

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet (1997) 1.30

Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med (2007) 1.29

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med (1998) 1.29

Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS (1997) 1.27

Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis (1990) 1.26

Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology (1980) 1.23

HIV infection of rectal mucosa. Lancet (1988) 1.22

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS (2000) 1.21

B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS (2000) 1.20

Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. J Nutr (2001) 1.20

Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis (1998) 1.18

Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med (2006) 1.18

Human cytotoxic T cell clones directed at autologous virus-transformed targets: further evidence for linkage of genetic restriction to T4 and T8 surface glycoproteins. J Immunol (1983) 1.18

Antibody response to human immunodeficiency virus after primary infection. J Infect Dis (1987) 1.17

Quinolinic acid production is related to macrophage tropic isolates of HIV-1. J Neurovirol (1995) 1.17

Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet (2006) 1.17

Behcet's syndrome: clinical, immunological and therapeutic evaluation of 17 patients. Aust N Z J Med (1974) 1.17

Gastrointestinal viral infections in homosexual men who were symptomatic and seropositive for human immunodeficiency virus. J Infect Dis (1988) 1.15

Immunoregulatory human T lymphocytes triggered as a consequence of viral infection: clonal analysis of helper, suppressor inducer and suppressor effector cell populations. J Immunol (1983) 1.14

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS (2000) 1.13

Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients. AIDS (1994) 1.12

Cigarettes, cough, and cancer of the lung. JAMA (1966) 1.12

Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins: baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study. J Nutr (1999) 1.12

Antiretroviral therapy of HIV-1 infection: established treatment strategies and new therapeutic options. Curr Opin Microbiol (2000) 1.11

Eastern equine encephalitis in a horse from southwestern Ontario. Can Vet J (1995) 1.11

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3. J Infect Dis (2000) 1.11

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS (2001) 1.10

Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection. J Infect Dis (2001) 1.10

Evidence for an excess of B→D*τ(-)ν(τ) decays. Phys Rev Lett (2012) 1.10

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group. J Infect Dis (1998) 1.09

HIV seroconversion illness. Med J Aust (1993) 1.09

Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA (1966) 1.09